RxSight, Inc.RXSTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

12 analysts·Moderate coverage

25%

Rating Distribution

Strong Buy

00%

Buy

325%

Hold

758%

Sell

217%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 24% higher.

Bear Case

$10.00

+20%

Consensus

$10.33

+24%

Bull Case

$11.00

+32%

Price Range12 analysts

Low

Consensus

High

$10.00

$11.00

Current Target

Current Price

$8.35

Upside to Target

$1.98

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.11(6 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+10.09%

EPS—

FY2028

Rev+7.29%

EPS—

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+20.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 20, 2026Piper Sandler

RxSight price target raised to $11 from $10 at Piper Sandler

Target:$11.00

+12.1%from $9.81

Dec 2, 2025Morgan Stanley

RxSight price target raised to $10 from $9 at Morgan Stanley

Target:$10.00

-14.2%from $11.65

Nov 6, 2025Stifel Nicolaus

RxSight price target raised to $10 from $8 at Stifel

Target:$10.00

+14.5%from $8.73

Oct 29, 2024Barclays

This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Target:$110.00

+111.5%from $52.00

Oct 29, 2024Guggenheim

This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Target:$52.00

+0.0%from $52.00

Oct 29, 2024Mizuho Securities

This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Target:$67.00

+28.8%from $52.00

Oct 29, 2024Jefferies

Jefferies Starts RxSight Inc. (RXST) at Buy

Target:$72.00

+43.3%from $50.25

Sep 23, 2024BTIG

BTIG Reiterates Buy Rating on RxSight Inc. (RXST)

Target:$59.00

+11.4%from $52.98

Sep 13, 2024Needham

Needham Reiterates Buy Rating on RxSight Inc. (RXST)

Target:$66.00

+21.0%from $54.54

Aug 6, 2024Stifel Nicolaus

RxSight Analysts Slash Their Forecasts After Q2 Results

Target:$65.00

+59.4%from $40.78

Aug 6, 2024Needham

RxSight Inc. (RXST) PT Lowered to $54 at Needham

Target:$54.00

+14.5%from $47.15

May 7, 2024Oppenheimer

RxSight Inc. (RXST) PT Raised to $72 at Oppenheimer

Target:$72.00

+14.6%from $62.84

May 7, 2024Needham

RxSight Inc. (RXST) PT Raised to $75 at Needham

Target:$75.00

+19.4%from $62.84

May 7, 2024Stifel Nicolaus

RxSight Inc. (RXST) PT Raised to $75 at Stifel

Target:$75.00

+19.4%from $62.84

May 7, 2024Wells Fargo

RxSight Inc. (RXST) PT Raised to $68 at Wells Fargo

Target:$68.00

+8.2%from $62.84

May 7, 2024BTIG

RxSight Inc. (RXST) PT Raised to $72 at BTIG

Target:$72.00

+14.6%from $62.84

May 6, 2024Stifel Nicolaus

RxSight price target raised to $68 from $64 at Stifel

Target:$68.00

+10.2%from $61.68

Dec 13, 2023Wells Fargo

Wells Fargo Upgrades RxSight Inc. (RXST) to Overweight

Target:$42.00

+5.6%from $39.78

Jul 12, 2023Needham

RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+

Target:$34.00

+10.2%from $30.86

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance